What 'success' means in cartilage repair — and why it matters here

Three numbers appear repeatedly across ChondroFiller studies, and understanding what each one measures makes the 3–5-year figures immediately readable rather than abstract.

The first is the IKDC score (International Knee Documentation Committee) or its hip equivalent, the mHHS — patient-reported scales that capture pain, stiffness, and ability to return to activity. The threshold that matters is 16.7 points: that is the minimum clinically important difference (MCID), the smallest gain on the IKDC scale that patients actually notice in daily life. Any improvement below it is statistically real but practically negligible; anything above it represents meaningful change.

The second is the MOCART score — an MRI-based measure of how completely a cartilage defect has been filled, rated 0 to 100. Scores in the 70–87 range, consistently seen across published ChondroFiller cohorts, indicate clinically meaningful structural fill rather than an empty or partially reconstructed defect.

The third is a simpler binary: whether patients report substantial symptom relief — pain reduced, function restored to a level that changes how they live.

The reason the 3–5-year window is the focus here is straightforward: earlier readings capture recovery trajectory, but three to five years is where the evidence tests whether those gains hold rather than fade.

The headline figure across joints

Across the published ChondroFiller evidence base, 70–85% of treated patients achieve meaningful symptom relief — a range that holds consistently across knee, hip, and small-joint applications and represents the headline figure at three to five years.

The strongest single long-term anchor for that range is a prospective hip cohort published by Mazek in 2021 (n=26). Of the 21 evaluable patients at follow-up, 17 — 81% — maintained good or excellent results at the three-, four-, and five-year time points, with statistically significant functional improvement from baseline recorded at each. Because it tracks the same patients continuously across the full 3–5-year window rather than capturing a single end-point, Mazek 2021 is the most cited long-term data point in the ChondroFiller literature. The patients in that cohort were treated via arthroscopic placement; this is the published clinical-evidence background that establishes what the scaffold can achieve, and it sits separately from how the treatment is currently delivered as an outpatient procedure in the UK.

Confidence in the 70–85% range is reinforced by its consistency across independent European investigations. Knee cohorts, the hip series, and a 2025 study of wrist cartilage defects in 25 patients all return figures within the same band. The cross-joint breadth matters: a success range that holds from large load-bearing joints to the distal radius carries more evidential weight than a knee-only estimate.

The appropriate register for that range is a directional guide grounded in real-world cohort data — not a guaranteed personal probability for any individual patient.

Knee outcomes in detail — functional scores and durability

For knee patients, the evidence is specific enough to address two practical questions: how much improvement is realistic, and how long does it last?

On improvement, four independent clinical investigations report an average IKDC gain of approximately 30 points — roughly double the MCID. At that scale, gains typically correspond to a marked reduction in pain on stairs and a return to sustained walking and moderate sport for patients who could not reliably manage either before treatment.

The Jerosch et al. post-market study provides the most robust durability anchor: a 32.4-point IKDC gain that held — and marginally increased — at three-year follow-up, where the cohort reached a mean functional score of 80. That trajectory confirms the gains were not eroded across the follow-up period; they persisted through it.

On the pace of recovery, a 2024 knee cohort (n=17, mean age 31) supplies the detail most useful for setting expectations. Lysholm and IKDC scores improved significantly at three, six, and twelve months (p<0.05 at each time point), but the difference between the six-month and twelve-month readings was not statistically significant. The practical inference is that the bulk of functional recovery consolidates within the first six months after the injection procedure. The 3–5-year durability figures therefore describe a sustained plateau rather than a gradual accumulation — most patients reach their new functional level relatively quickly and, in the majority of cases documented, hold it.

What MRI shows — defect fill, fibrocartilage, and how the scaffold works

The most useful window into structural progress comes from the randomised ChondroFiller-versus-microfracture study (2016), which tracked MOCART over time rather than at a single end-point: scores rose from 65.3 at four weeks to 81.6 at 52 weeks — a trajectory that illustrates progressive defect fill across the first year of healing. The wider picture, spanning European cohorts treating the knee, hip, and wrist, places final MOCART values in the 70–87 band, indicating clinically meaningful fill in the large majority of cases.

What that fill actually represents is worth stating plainly. The tissue that forms inside the scaffold is fibrocartilage, not native hyaline cartilage. The two share a broadly similar function but differ in composition and biomechanical properties; MRI confirming a filled defect does not mean the joint has been restored to its original state.

The scaffold works by matrix-induced chondrogenesis: once the injectable collagen gel sets in the defect, it recruits the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — into a structured repair environment. A 2025 ex vivo model corroborates this mechanism directly, showing a 2.4-fold increase in DNA content within the scaffold by day 14, consistent with active cell migration into the matrix.

The honest framing, borne out by both the MRI data and the cellular evidence, is that the ChondroFiller injection promotes endogenous repair rather than guaranteeing regeneration of the original cartilage architecture.

Who gets the best results — and where the evidence is weaker

Patient selection is the single strongest predictor of outcome at three to five years, and the evidence is consistent enough to draw a reasonably clear line.

The profile where the published figures are most applicable is an adult typically under 50, presenting with an isolated focal cartilage defect in a well-aligned joint with intact ligaments. Patients matching that profile account for the majority of the 70–85% success range covered in earlier sections. Outside it, the picture changes materially: Tönnis grade 2–3 osteoarthritis — where degenerative change is widespread rather than focal — is consistently associated with poor outcomes in the Mazek 2021 cohort and across the broader literature. The ChondroFiller injection is not indicated for generalised degenerative joint disease, and outcomes in that group are sufficiently poor that the procedure would typically not be offered.

One mechanical finding is worth understanding in practical terms. A 2024 biomechanical in-vitro study found that ChondroFiller did not reduce damage to the opposing cartilage surface in the early post-procedure phase, attributed to the implant's initial mechanical instability before the scaffold integrates. This supports the standard clinical requirement for approximately six weeks of protected weight-bearing after the injection. It is not a reason to avoid the procedure where the indication is correct — it is a reason to follow the rehabilitation protocol.

Reoperation rates across published series are reported at 3–8%, which is low relative to the surgical alternatives ChondroFiller is designed to defer.

On the evidence base itself: the published data consists predominantly of small, non-randomised European cohorts. The sole randomised trial is compromised by a high control-arm dropout — six of ten microfracture patients refused allocated surgery — making any head-to-head comparison statistically invalid. That caveat is real, but it sits alongside a global case volume of more than 19,000 procedures, which provides procedural confidence even where large controlled-trial data remain absent.

What the evidence means if you are considering treatment

The practical question worth arriving at — after reviewing the IKDC trajectories, MOCART data, and patient-selection evidence — is not 'does ChondroFiller work?' but 'does my presentation match the profile where it works?' For adults with an isolated focal defect, normal alignment, and no background osteoarthritis, the 70–85% signal is a genuine and durable finding. For those outside that profile — older patients, wider degenerative change, malalignment — the evidence thins considerably, and a realistic estimate requires direct clinical judgement.

That assessment is the appropriate next step. It translates population-level data into an individual answer: defect size, location, imaging findings, and joint condition all shift the picture in ways no published series can replicate.

In the UK, Liquid Cartilage™ — the ChondroFiller injectable collagen scaffold — is available as an ultrasound-guided outpatient treatment at the London Cartilage Clinic on Harley Street. Professor Paul Y. F. Lee delivers the procedure; the published literature acknowledges that technique precision is a material determinant of outcomes, making clinician experience relevant alongside the data reviewed here.

Assessments and further information are available at londoncartilage.com.

1. [1] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
5. [5] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z